Ixaka
Laurent is a serial biotech entrepreneur and senior executive in the industry. He is co-founder, CEO & Chairman of Parthenon Therapeutics, a precision oncology biotech based in Boston. Laurent has completed pharma/biotech transactions worth over $3B in biobucks and raised > $250M. He is an inventor and authored over 70 papers and patents.
Laurent has led and/or contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $3B in annual sales.
Laurent has also led business and R&D functions in both pharma and biotech (US and EU), including CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities.
He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of an American Heart Association Fellowship.
This person is not in the org chart
This person is not in any offices
Ixaka
1 followers
Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.